Browse the evidence

Incretin-based anti-obesity medications (GLP-1 and GIP/GLP-1 receptor agonists) cause gastrointestinal adverse effects (nausea, diarrhea, constipation) in 65–84% of patients, primarily through delayed gastric emptying and central appetite signaling activation.

If you start a GLP-1 or GIP medication, expect stomach issues like nausea or diarrhea in the first few weeks. This is very common (affecting up to 84% of users). To manage it, start with a low dose and increase slowly. Eat small, low-fat meals, stay hydrated, and avoid spicy or fatty foods. Most symptoms improve as your body adjusts.

Rapid weight loss, whether from very-low-calorie diets or bariatric surgery, significantly increases the risk of gallstone formation (cholelithiasis) due to bile supersaturation and reduced gallbladder motility.

If you lose weight very quickly (e.g., through surgery or extreme dieting), you are at higher risk for gallstones. To prevent this, aim for gradual weight loss. If you have had bariatric surgery, doctors often prescribe Ursodeoxycholic acid (UDCA) for 6 months to prevent gallstones.

Administering GLP-1 receptor agonists (liraglutide or semaglutide) during the proestrus/estrus (P/E) phase of the estrous cycle significantly enhances food intake suppression and body weight loss compared to administration during the metestrus/diestrus (M/D) phase in female rats.

If you are using a GLP-1 medication like semaglutide or liraglutide, your body's natural hormonal cycle may affect how well it works. This research suggests that taking your dose during the weeks when estrogen is highest (typically the first half of the cycle) might lead to greater appetite suppression and weight loss than taking it during other weeks. While more research in humans is needed, you might consider discussing cycle-timing with your provider to see if optimizing the timing of your injections could enhance your results.

Inhibiting PCSK9, NF-κB, and NLRP3 reduces cholesterol and inflammation, providing cardioprotection.

For cardiovascular protection, medications that lower cholesterol (like PCSK9 inhibitors) and reduce inflammation (targeting NF-κB or NLRP3) are effective strategies. These treatments help manage risk factors associated with heart disease and metabolic disorders. Discuss with your healthcare provider if these targeted therapies are suitable for your cardiovascular health.

Dulaglutide, subcutaneous semaglutide, and tirzepatide exhibit comparable risks of severe gastrointestinal adverse events (including acute pancreatitis, biliary disease, bowel obstruction, gastroparesis, and severe constipation) in adults with type 2 diabetes.

If you are choosing between dulaglutide, semaglutide, or tirzepatide for type 2 diabetes, do not expect a significant difference in the risk of serious stomach problems (like pancreatitis or bowel obstruction) between them. They all carry a similar, low risk of severe GI events, though mild nausea or diarrhea is common with all. Your choice should likely be based on efficacy (weight loss/glycemic control), cost, and tolerability of mild side effects rather than fear of severe GI complications.

Bariatric surgery (RYGB or SG) improves peripheral insulin sensitivity only after substantial weight loss (>30%) is achieved at 1 year, whereas low-calorie diet (LCD) fails to improve insulin sensitivity despite initial weight loss, indicating that the magnitude of weight loss, not the surgical mechanism itself, drives late-stage insulin sensitivity improvements.

If you undergo bariatric surgery, do not expect immediate improvements in insulin sensitivity. The metabolic benefits, such as improved insulin sensitivity, typically take about a year to manifest and are directly tied to the amount of weight you lose. If you do not lose significant weight, your insulin sensitivity may not improve, regardless of the surgery type.

Obesity promotes cancer development by increasing DNA damage and impairing DNA repair mechanisms, while simultaneously activating pro-survival signaling pathways that prevent the elimination of damaged cells.

Maintaining a healthy weight is a critical strategy for reducing cancer risk, not just for metabolic health. Obesity creates a biological environment that damages DNA and prevents the body from fixing those damages, while also protecting damaged cells from dying. Weight management interventions should be viewed as a direct cancer prevention strategy.

Periconceptional exposure to GLP-1 receptor agonists (liraglutide or semaglutide) is associated with an increased risk of preterm birth, but this risk is confined to women using the medication for diabetes treatment and is not observed in women using it for weight management.

If you are using a GLP-1 medication (like Ozempic or Saxenda) and planning pregnancy, talk to your doctor. If you have diabetes, the increased risk of early delivery is likely due to the diabetes, not the drug, so managing your blood sugar is key. If you are using it for weight loss, current large-scale data shows no increased risk of early delivery, which may help alleviate anxiety about inadvertent exposure.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides vasculoprotective and anti-atherosclerotic benefits by stimulating endothelial progenitor cell mobilization, enhancing nitric oxide synthase activity, and suppressing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).

If you have Type 2 Diabetes or obesity with cardiovascular risk factors, Tirzepatide is not just a weight-loss drug. It actively protects your blood vessels by improving endothelial function and reducing inflammation. The standard protocol starts at a low dose (2.5 mg) once weekly and titrates up to 15 mg based on tolerance and glycemic goals. It is administered via subcutaneous injection alongside lifestyle changes.

Current incretin-based therapies (GLP-1 and GLP-1/GIP agonists) primarily reduce body weight through decreased food intake, but they fail to increase energy expenditure (EE) and often cause a compensatory drop in basal metabolic rate, which hinders sustainable weight loss.

If you are using GLP-1 medications like semaglutide or tirzepatide, expect significant weight loss primarily from eating less, not from burning more calories. Be aware that your body will likely slow down its resting metabolism as you lose weight, which can make maintaining loss difficult. This is a known biological adaptation, not a personal failure. Future treatments may combine appetite suppression with energy expenditure boosting to overcome this.

Hypoglycemia occurs in approximately 9% of GLP-1/GIP RA emergency exposures, a rate higher than previously reported, even in the absence of concomitant hypoglycemic medications.

Be aware that GLP-1 medications can cause low blood sugar, even if you aren't taking insulin. This is more likely if you skip meals, exercise heavily, or take a higher dose. Monitor your blood sugar if you feel shaky, dizzy, or confused, and treat lows with fast-acting carbohydrates.

Short-term overnutrition directly impairs thyroid hormone biosynthesis and peripheral T4-to-T3 conversion, causing hypothyroidism and reduced energy expenditure, despite compensatory thyroidal adaptations.

Obesity can directly damage thyroid function and slow metabolism, creating a vicious cycle. However, this damage is largely reversible with weight loss. Focus on sustainable caloric reduction rather than seeking thyroid fixes alone, as the thyroid dysfunction is a symptom of overnutrition, not the root cause.

Overnutrition reduces whole-body energy expenditure by impairing peripheral T4-to-T3 conversion via decreased D2 activity, rendering obese individuals resistant to T4 therapy.

Obesity impairs your body's ability to convert T4 into active T3, which lowers your metabolism and makes T4 supplements less effective for weight loss. The solution is not more thyroid medication, but weight loss, which restores normal thyroid function.

Tirzepatide administration (2.5-15 mg weekly) causes injection-site reactions (ISRs) in 2-8% of patients, presenting as localized erythema, swelling, or pruritus, which are generally mild, self-limiting, and comparable in frequency to other GLP-1 agonists.

Expect mild redness or itching at the injection site in the first few weeks. This is common and usually goes away on its own. Rotate your injection sites (abdomen, thigh, upper arm) and use clean needles to reduce irritation. If you get a rash that spreads or doesn't go away, contact your doctor.

Tirzepatide use is associated with rare but serious hypersensitivity reactions, including anaphylaxis and angioedema, occurring in approximately 1-4% of patients, often linked to anti-drug antibodies but not always causally related.

Watch for signs of a severe allergic reaction, such as swelling of the face/throat, difficulty breathing, or widespread hives. These are rare but serious. If you experience them, seek emergency medical help immediately. Most skin reactions are mild and go away on their own.

Excess and dysfunctional epicardial adipose tissue (EAT) contributes to coronary microvascular dysfunction (CMD) and vasospastic angina (VSA) through pro-inflammatory signaling, oxidative stress, and smooth muscle hyperreactivity.

If you have chest pain with normal arteries (CMD or VSA), reducing epicardial fat through lifestyle or medication may improve symptoms by lowering inflammation and improving blood vessel function.

GLP-1 receptor agonist utilization for obesity has increased significantly and disproportionately among women compared to men, with obesity emerging as a key predictor of use specifically in female patients.

If you are a woman with obesity, you are significantly more likely to be prescribed a GLP-1RA than a man with similar characteristics, particularly after 2021. This utilization gap is driven by stronger associations between obesity and prescription in women. Men should be aware that they may face lower prescription rates and should proactively discuss weight management options with their providers.

Depression is uniquely and significantly associated with increased GLP-1RA utilization in women, suggesting a complex interplay between mental health comorbidities and medication access.

For women, having a diagnosis of depression is linked to a higher likelihood of being prescribed GLP-1RAs. This may reflect targeted prescribing or the complex relationship between mental health and weight management. It highlights the need for sex-sensitive screening and holistic care that addresses both metabolic and psychiatric health.

There are confirmed cases of falsified GLP-1 receptor agonists in Brazil, indicating supply chain vulnerabilities.

Counterfeit GLP-1 drugs have been confirmed in Brazil. Patients should obtain medications through regulated channels to avoid falsified products.

The presence of anti-drug antibodies (ADAs) to GLP-1 receptor agonists does not necessarily neutralize their clinical efficacy, although it may increase the risk of hypersensitivity reactions.

If you develop antibodies to your GLP-1 medication, it does not automatically mean it has stopped working for weight loss. However, you may experience more injection site reactions. Discuss these symptoms with your doctor; they may not need to stop the drug unless side effects are severe.

GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.

GLP-1 therapies can significantly improve liver health in patients with MASH, including resolving the disease and improving fibrosis in many cases. This benefit is partly due to weight loss but also involves direct effects on liver tissue. Early treatment is crucial, as benefits are not seen in advanced cirrhosis. Patients with fatty liver should discuss these options with their doctor.

GLP-1 receptor agonists (GLP-1RAs) cause frequent, dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, reflux) that typically diminish over time but are a major cause of treatment discontinuation.

If you start a GLP-1 medication, expect digestive issues like nausea or diarrhea in the first few months. These symptoms are very common (affecting half to 60% of users) and are usually dose-dependent. The good news is that they typically get better over time. Starting with a lower dose and increasing slowly can help manage this.

GLP-1RAs are associated with an increased risk of hypoglycemia, particularly when combined with insulin or sulfonylureas, although the risk remains lower than with those agents alone.

If you take a GLP-1 medication along with insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) increases. However, this risk is still lower than if you were taking insulin or sulfonylureas alone. Monitor your blood sugar as advised by your doctor.

Targeting HDL-C and Triglycerides with non-statin drugs (niacin, fibrates) added to statins does not provide additional cardiovascular benefit compared to statin therapy alone in most cases.

If you are already taking a statin, adding niacin or fibrates to fix your HDL or triglycerides usually does not provide extra protection against heart attacks. Stick to your statin and lifestyle changes, as these are the most proven strategies.